Journal
CHILDREN-BASEL
Volume 6, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/children6100108
Keywords
atopic dermatitis; psoriasis; inflammation; cytokine; skin-barrier; topical therapy; systemic therapy; biologic therapy
Categories
Funding
- Dermatology Foundation
- National Institutes of Health [T32AR060710]
Ask authors/readers for more resources
Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available